Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
VIR: Notice of proposed insider sale following restricted stock vesting. The filing reports 1,634 restricted common shares vested on 02/23/2026 as issuer compensation. It also discloses that Jason V. O'Byrne sold 2,089 common shares on 02/23/2026 for $15,568.90.
Brent Sabatini filed a Form 144 reporting a proposed sale of Common stock tied to a Restricted Stock Vesting event dated 02/23/2026 for 1430 shares. The excerpt also lists securities recorded as sold during the prior three months: 1530 on 02/13/2026 and 1829 on 02/23/2026.
Vanina A. Huard De Verneuil reported a Rule 144 notice to sell common stock tied to restricted stock vesting. The filing lists 3,117 shares to be sold on 02/23/2026 as part of a compensation vesting event and shows 4,445 shares sold during the past three months on 02/23/2026.
VIR filed a Rule 144 notice reporting proposed sales of common stock. The filing lists an exercise of stock options and a sale quantity of 20,377 shares on 02/24/2026 for cash. It also lists prior 10b5-1 sales by Vicki Lee Sato of 22,000 shares on 02/02/2026 for $169,670.60, 22,000 shares on 01/02/2026 for $130,383.00, and 22,000 shares on 12/01/2025 for $132,070.40.
Vir Biotechnology is offering $200,000,000 of its common stock in a primary offering pursuant to a preliminary prospectus supplement dated February 24, 2026. The prospectus supplement states the offering is subject to completion and includes an underwriter option to purchase up to $30,000,000 of additional shares.
The filing discloses a recently executed Collaboration and License Agreement and Stock Purchase Agreement with Astellas dated February 19, 2026, under which Vir would receive $335 million in upfront and near-term consideration (including a $240 million cash upfront payment and a $75 million equity investment), and may receive up to $1.37 billion in future milestones, with global development costs for VIR-5500 shared 40% by Vir and 60% by Astellas. Shares outstanding were 139,474,954 as of December 31, 2025.
Vir Biotechnology is a clinical-stage biopharma company focused on serious infectious diseases and cancer, using antibody discovery, AI-enabled engineering and the PRO-XTEN® masking platform to power the immune system against viruses and solid tumors.
The company’s lead program is the tobevibart and elebsiran combination for chronic hepatitis delta, where Phase 2 data showed high rates of undetectable HDV RNA and hepatitis B surface antigen suppression, and three registrational ECLIPSE trials are underway with topline results expected in late 2026 and early 2027. Vir has also decided not to move this combination into Phase 3 for chronic hepatitis B after mixed cure-rate data.
In oncology, Vir is advancing three dual-masked T-cell engagers—VIR-5500 for prostate cancer, VIR-5818 for HER2-positive tumors, and VIR-5525 for EGFR-expressing tumors—with early Phase 1 data showing dose-dependent tumor shrinkage and manageable cytokine release. A broad preclinical pipeline of additional PRO-XTEN® TCEs targets multiple solid tumors.
The company strengthened its partnering base through multiple strategic deals. A global collaboration with Astellas around VIR-5500 includes $335 million in upfront and near-term consideration, shared global development costs, equal U.S. profit-sharing and significant future milestones and royalties. A license with Norgine brought €55 million in initial development cost reimbursement plus up to €495 million in milestones and mid-teen to high-twenties percent royalties for the hepatitis delta combination in Europe, Australia and New Zealand. Vir also licensed the PRO-XTEN® technology and three masked TCEs from Sanofi for $100 million upfront and a $75 million milestone tied to first-in-human dosing of VIR-5525, with substantial future milestones and royalties, and maintains legacy collaborations with GSK, Alnylam, Brii Biosciences, the Gates Foundation and others that support its infectious disease pipeline.
Vir Biotechnology is a clinical-stage biopharma company focused on serious infectious diseases and cancer, using antibody discovery, AI-enabled engineering and the PRO-XTEN® masking platform to power the immune system against viruses and solid tumors.
The company’s lead program is the tobevibart and elebsiran combination for chronic hepatitis delta, where Phase 2 data showed high rates of undetectable HDV RNA and hepatitis B surface antigen suppression, and three registrational ECLIPSE trials are underway with topline results expected in late 2026 and early 2027. Vir has also decided not to move this combination into Phase 3 for chronic hepatitis B after mixed cure-rate data.
In oncology, Vir is advancing three dual-masked T-cell engagers—VIR-5500 for prostate cancer, VIR-5818 for HER2-positive tumors, and VIR-5525 for EGFR-expressing tumors—with early Phase 1 data showing dose-dependent tumor shrinkage and manageable cytokine release. A broad preclinical pipeline of additional PRO-XTEN® TCEs targets multiple solid tumors.
The company strengthened its partnering base through multiple strategic deals. A global collaboration with Astellas around VIR-5500 includes $335 million in upfront and near-term consideration, shared global development costs, equal U.S. profit-sharing and significant future milestones and royalties. A license with Norgine brought €55 million in initial development cost reimbursement plus up to €495 million in milestones and mid-teen to high-twenties percent royalties for the hepatitis delta combination in Europe, Australia and New Zealand. Vir also licensed the PRO-XTEN® technology and three masked TCEs from Sanofi for $100 million upfront and a $75 million milestone tied to first-in-human dosing of VIR-5525, with substantial future milestones and royalties, and maintains legacy collaborations with GSK, Alnylam, Brii Biosciences, the Gates Foundation and others that support its infectious disease pipeline.
Vir Biotechnology is a clinical-stage biopharma company focused on serious infectious diseases and cancer, using antibody discovery, AI-enabled engineering and the PRO-XTEN® masking platform to power the immune system against viruses and solid tumors.
The company’s lead program is the tobevibart and elebsiran combination for chronic hepatitis delta, where Phase 2 data showed high rates of undetectable HDV RNA and hepatitis B surface antigen suppression, and three registrational ECLIPSE trials are underway with topline results expected in late 2026 and early 2027. Vir has also decided not to move this combination into Phase 3 for chronic hepatitis B after mixed cure-rate data.
In oncology, Vir is advancing three dual-masked T-cell engagers—VIR-5500 for prostate cancer, VIR-5818 for HER2-positive tumors, and VIR-5525 for EGFR-expressing tumors—with early Phase 1 data showing dose-dependent tumor shrinkage and manageable cytokine release. A broad preclinical pipeline of additional PRO-XTEN® TCEs targets multiple solid tumors.
The company strengthened its partnering base through multiple strategic deals. A global collaboration with Astellas around VIR-5500 includes $335 million in upfront and near-term consideration, shared global development costs, equal U.S. profit-sharing and significant future milestones and royalties. A license with Norgine brought €55 million in initial development cost reimbursement plus up to €495 million in milestones and mid-teen to high-twenties percent royalties for the hepatitis delta combination in Europe, Australia and New Zealand. Vir also licensed the PRO-XTEN® technology and three masked TCEs from Sanofi for $100 million upfront and a $75 million milestone tied to first-in-human dosing of VIR-5525, with substantial future milestones and royalties, and maintains legacy collaborations with GSK, Alnylam, Brii Biosciences, the Gates Foundation and others that support its infectious disease pipeline.
Vir Biotechnology entered a global collaboration with Astellas to co-develop and co-commercialize VIR-5500, its PSMA-targeting PRO-XTEN® T‑cell engager for prostate cancer. Vir will receive $335 million in upfront and near-term payments, including $240 million in cash and a $75 million equity investment, plus a $20 million milestone tied to manufacturing tech transfer.
Vir is eligible for up to $1.37 billion in additional milestones and tiered double‑digit ex‑U.S. royalties, while sharing U.S. profits 50/50 if it keeps co-promotion rights. Astellas will buy 7,239,382 Vir shares at $10.36, a 50% premium to the 30‑day VWAP. Updated Phase 1 data for VIR‑5500 in metastatic prostate cancer show no dose‑limiting toxicities, grade ≥3 treatment‑related events in 12% of patients, and in higher-dose cohorts PSA50 responses in 82% of evaluable patients and a 45% objective response rate in RECIST‑evaluable patients.
For 2025, Vir reported revenue of $68.6 million, a net loss of $438.0 million (improved from $522.0 million in 2024), and cash, cash equivalents and investments of $781.6 million as of December 31, 2025. The company expects its cash, including effects of the Astellas deal, to fund operations into the second quarter of 2028.
Vir Biotechnology entered a global collaboration with Astellas to co-develop and co-commercialize VIR-5500, its PSMA-targeting PRO-XTEN® T‑cell engager for prostate cancer. Vir will receive $335 million in upfront and near-term payments, including $240 million in cash and a $75 million equity investment, plus a $20 million milestone tied to manufacturing tech transfer.
Vir is eligible for up to $1.37 billion in additional milestones and tiered double‑digit ex‑U.S. royalties, while sharing U.S. profits 50/50 if it keeps co-promotion rights. Astellas will buy 7,239,382 Vir shares at $10.36, a 50% premium to the 30‑day VWAP. Updated Phase 1 data for VIR‑5500 in metastatic prostate cancer show no dose‑limiting toxicities, grade ≥3 treatment‑related events in 12% of patients, and in higher-dose cohorts PSA50 responses in 82% of evaluable patients and a 45% objective response rate in RECIST‑evaluable patients.
For 2025, Vir reported revenue of $68.6 million, a net loss of $438.0 million (improved from $522.0 million in 2024), and cash, cash equivalents and investments of $781.6 million as of December 31, 2025. The company expects its cash, including effects of the Astellas deal, to fund operations into the second quarter of 2028.
Vir Biotechnology entered a global collaboration with Astellas to co-develop and co-commercialize VIR-5500, its PSMA-targeting PRO-XTEN® T‑cell engager for prostate cancer. Vir will receive $335 million in upfront and near-term payments, including $240 million in cash and a $75 million equity investment, plus a $20 million milestone tied to manufacturing tech transfer.
Vir is eligible for up to $1.37 billion in additional milestones and tiered double‑digit ex‑U.S. royalties, while sharing U.S. profits 50/50 if it keeps co-promotion rights. Astellas will buy 7,239,382 Vir shares at $10.36, a 50% premium to the 30‑day VWAP. Updated Phase 1 data for VIR‑5500 in metastatic prostate cancer show no dose‑limiting toxicities, grade ≥3 treatment‑related events in 12% of patients, and in higher-dose cohorts PSA50 responses in 82% of evaluable patients and a 45% objective response rate in RECIST‑evaluable patients.
For 2025, Vir reported revenue of $68.6 million, a net loss of $438.0 million (improved from $522.0 million in 2024), and cash, cash equivalents and investments of $781.6 million as of December 31, 2025. The company expects its cash, including effects of the Astellas deal, to fund operations into the second quarter of 2028.